Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:PARN
- CUSIP: N/A
- Web: www.parnell.com/
- 50 Day Moving Avg: $1.03
- 200 Day Moving Avg: $1.38
- 52 Week Range: $0.65 - $3.95
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.21
- P/E Growth: 0.0000
- Net Margins: -130.46%
- Return on Equity: -83.86%
- Return on Assets: -43.24%
- Debt-to-Equity Ratio: 0.82%
- Current Ratio: 0.61%
- Quick Ratio: 0.37%
- Average Volume: 85,051 shs.
- Beta: 0.14
Frequently Asked Questions for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
What is Parnell Pharmaceuticals Holdings Ltd's stock symbol?
Parnell Pharmaceuticals Holdings Ltd trades on the NASDAQ under the ticker symbol "PARN."
Who are some of Parnell Pharmaceuticals Holdings Ltd's key competitors?
Some companies that are related to Parnell Pharmaceuticals Holdings Ltd include Johnson & Johnson (JNJ), Roche Holding (RHHBY), Novartis AG (NVS), Pfizer (PFE), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Medtronic PLC (MDT), AbbVie (ABBV), Celgene Corporation (CELG), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Allergan PLC. (AGN).
Who are Parnell Pharmaceuticals Holdings Ltd's key executives?
Parnell Pharmaceuticals Holdings Ltd's management team includes the folowing people:
- Alan Bell, Chairman of the Board
- Robert Joseph, President, Chief Executive Officer, Director
- Brad McCarthy, Chief Financial Officer, Director
- Edward J. Robb, Chief Scientific Officer
- Matthew Musselman, Chief Commercial Officer
- Peter Molloy, Independent Director
- Andrew J. Want, Independent Director
How do I buy Parnell Pharmaceuticals Holdings Ltd stock?
Shares of Parnell Pharmaceuticals Holdings Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Parnell Pharmaceuticals Holdings Ltd's stock price today?
MarketBeat Community Rating for Parnell Pharmaceuticals Holdings Ltd (NASDAQ PARN)MarketBeat's community ratings are surveys of what our community members think about Parnell Pharmaceuticals Holdings Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Parnell Pharmaceuticals Holdings Ltd stock can currently be purchased for approximately $0.69.
Consensus Ratings for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
(Data available from 7/27/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/24/2016||Dawson James||Reiterated Rating||Buy||N/A|
|4/1/2016||Jefferies Group LLC||Reiterated Rating||Buy||$18.00 -> $16.00||N/A|
|2/29/2016||Piper Jaffray Companies||Reiterated Rating||Overweight||$12.00 -> $9.00||N/A|
Earnings History for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)Earnings History by Quarter for Parnell Pharmaceuticals Holdings Ltd (NASDAQ PARN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
Current Year EPS Consensus Estimate: $-1.5200 EPS
Next Year EPS Consensus Estimate: $-0.5700 EPS
Dividend History for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
Latest Headlines for Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN)
Parnell Pharmaceuticals Holdings Ltd (PARN) Chart for Thursday, July, 27, 2017